CJC-1295 Without DAC: What It Is and How It Works

CJC-1295 without DAC is a synthetic growth hormone-releasing hormone (GHRH) analog that signals the pituitary to release growth hormone but clears the bloodstream in roughly 30 minutes instead of days. The without-DAC version — often labeled Mod GRF 1-29 — drops the Drug Affinity Complex that binds standard CJC-1295 to albumin, so it produces sharper, shorter GH pulses. It is sold as a research chemical and is not FDA-approved for human use.

What Is CJC-1295 Without DAC?

If you are wondering what is cjc-1295 without dac, the cleanest answer is that it is the first 29 amino acids of GHRH, modified with substitutions that resist enzymatic breakdown while keeping the peptide fast-acting. That short action is the whole point: the peptide is designed to work with the body's natural pulsatile GH rhythm rather than flattening it into one long elevation.

• Also known as: Mod GRF (1-29), CJC-1295 no DAC, CJC-1295 (Mod GRF)
• Peptide class: GHRH analog and growth hormone secretagogue
• Half-life: Approximately 30 minutes in circulation
• Target: GHRH receptors on pituitary somatotroph cells
• Regulatory status: Not approved by the FDA for human use; sold for laboratory research

CJC-1295 With DAC vs Without DAC

Both versions share the same GHRH backbone. The difference is a maleimide linker on the DAC version that attaches the peptide to albumin in the blood, turning a 30-minute peptide into one that circulates for about a week.

Feature	CJC-1295 with DAC	CJC-1295 without DAC
Half-life	About 6–8 days (albumin-bound)	About 30 minutes
Dosing frequency discussed	1–2 times per week	1–3 times per day
Growth hormone pattern	Sustained, elevated baseline	Pulsatile, closer to natural
Albumin binding	Yes	No
Common stacking partner	Ipamorelin or another GHRP	Ipamorelin or another GHRP
Typical research vial size	2 mg or 5 mg	2 mg or 5 mg

People weighing cjc-1295 with dac or without are usually trading convenience against control. The DAC version means fewer injections, while the non-DAC version lets users line up GH pulses with sleep, fasting, or training. The two are often treated as interchangeable, but their pharmacokinetics are genuinely different.

CJC-1295 Without DAC and Ipamorelin

CJC-1295 without DAC is most commonly paired with a growth hormone-releasing peptide such as ipamorelin. A GHRH analog plus a ghrelin-receptor agonist hits two pathways at once, which is why the combination dominates the research and bodybuilding literature. The pairing, often written as cjc-1295 ipamorelin no dac or cjc-1295 ipamorelin with dac depending on which GHRH version is used, is typically drawn into the same syringe.

Vial math matters here. A cjc-1295 without dac 5mg ipamorelin 5mg blend is usually reconstituted so that each unit of liquid delivers a fixed ratio of both peptides, which keeps dosing simple but leaves no room to adjust one peptide without adjusting the other.

Protocol element	Commonly cited range
CJC-1295 without DAC per dose	100–300 mcg
Ipamorelin per dose	100–300 mcg
Doses per day	1–3
Timing often reported	Before bed, on waking, or pre-workout

These figures come from animal studies and user forums rather than FDA-reviewed human trials. Anyone looking up cjc 1295 without dac and ipamorelin dosage should treat the numbers as background context, not a prescription.

Reported Benefits and Research Interest

Most of what gets discussed as cjc 1295 without dac benefits comes from rodent research and self-reported experience, not controlled human trials. The peptide's main scientific appeal is that it raises endogenous growth hormone production instead of introducing exogenous GH.

• Higher GH and IGF-1 levels after administration in animal models
• Pulsatile release that more closely mirrors natural secretion
• Research interest in body composition, recovery, and sleep quality
• Anecdotal reports about skin, joint, and connective tissue
• Interest as a lower-cost alternative to prescription GH therapy in fitness communities

None of these are established human outcomes. GHRH analog research is ongoing, but claims that the peptide cures disease or replaces medically supervised growth hormone treatment are not supported by the evidence.

Dosing Frequency and Practical Considerations

Because the half-life is short, the dosage per week for the non-DAC peptide is usually expressed as daily or twice-daily injections rather than one weekly shot. A frequently cited starting point is 100 mcg once or twice daily, with some protocols moving toward 200–300 mcg per dose.

The DAC version runs on a completely different schedule — often 1–2 mg once or twice weekly — which is the single biggest practical reason people pick one over the other. Splitting the shorter peptide into multiple smaller injections keeps GH pulses from overlapping and may reduce receptor desensitization.

Storage and handling also matter. Lyophilized powder should be kept cold and dry, and reconstituted peptide is typically refrigerated and used within a few weeks.

Safety, Sourcing, and Legal Status

CJC-1295 without DAC is not FDA-approved for human use in the United States, and it is legally sold only as a research chemical. Purity, sterility, and actual peptide content are not guaranteed the way they would be for a prescription drug.

• User-reported side effects include injection-site irritation, headache, flushing, and water retention
• Peptides can influence blood sugar and cortisol, so people with diabetes or hormone-sensitive conditions should be especially cautious
• Long-term human safety data is limited, and no standard human dose exists
• Anyone considering use should discuss it with a licensed healthcare professional first

Responsible sourcing means asking for third-party certificates of analysis, HPLC purity data, and cold-chain shipping. A vendor that will not share that information is not a vendor worth using.

COMMON QUESTIONS

Frequently Asked Questions

What is the difference between CJC-1295 with DAC and without DAC?

The DAC version carries a maleimide linker that binds the peptide to albumin, giving it a half-life of roughly 6 to 8 days and making it a once- or twice-weekly peptide. Without DAC, the half-life drops to about 30 minutes, so it is typically discussed as a one-to-three-times-daily injection. Both are GHRH analogs sold as research chemicals, not approved medicines.

Can CJC-1295 without DAC be stacked with ipamorelin?

It is the most frequently reported pairing because the two peptides act on different receptors: CJC-1295 without DAC hits GHRH receptors while ipamorelin hits ghrelin receptors. Reported doses usually fall between 100 and 300 mcg of each peptide per injection, one to three times daily. No human dose has been established, and the combination is not FDA-approved for human use.

Is CJC-1295 without DAC legal in the United States?

It is not FDA-approved for human use, but it can be legally sold as a research chemical intended for laboratory study only. Buying it for personal human consumption falls outside that research label and carries real risk, since product purity and sterility are not regulated. Talk to a licensed healthcare professional before considering any peptide product.